Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Beginning Cash Balance (2017 - 2020)

Northwest Biotherapeutics (NWBO) has 8 years of Beginning Cash Balance data on record, last reported at $315000.0 in Q4 2020.

  • For Q4 2020, Beginning Cash Balance changed N/A year-over-year to $315000.0; the TTM value through Dec 2020 reached $379000.0, up 15.2%, while the annual FY2020 figure was $379000.0, 15.2% up from the prior year.
  • Beginning Cash Balance reached $315000.0 in Q4 2020 per NWBO's latest filing, up from $64000.0 in the prior quarter.
  • Across five years, Beginning Cash Balance topped out at $764000.0 in Q3 2017 and bottomed at $41000.0 in Q4 2018.
  • Average Beginning Cash Balance over 4 years is $352500.0, with a median of $322000.0 recorded in 2019.
  • The widest YoY moves for Beginning Cash Balance: up 254.67% in 2018, down 88.29% in 2018.
  • A 4-year view of Beginning Cash Balance shows it stood at $350000.0 in 2017, then plummeted by 88.29% to $41000.0 in 2018, then surged by 702.44% to $329000.0 in 2019, then dropped by 4.26% to $315000.0 in 2020.
  • Per Business Quant database, its latest 3 readings for Beginning Cash Balance were $315000.0 in Q4 2020, $64000.0 in Q1 2020, and $329000.0 in Q1 2019.